Sopharma AD (BUL:SFA)

Market Cap	1.44B
Revenue (ttm)	2.51B
Net Income (ttm)	124.18M
Shares Out	519.26M
EPS (ttm)	0.44
PE Ratio	6.28
Forward PE	n/a
Dividend	0.05 (1.89%)
Ex-Dividend Date	Jul 10, 2025

Volume	59,913
Average Volume	45,543
Open	2.730
Previous Close	2.730
Day's Range	2.710 - 2.790
52-Week Range	1.840 - 2.790
Beta	-0.09
RSI	67.20
Earnings Date	Nov 30, 2025

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana to reduce the stress; and medical devices...

• Industry: Pharmaceutical Preparations
• Founded: 1933
• Employees: 5,599
• Stock Exchange: Bulgarian Stock Exchange
• Ticker Symbol: SFA

Financial Performance

In 2024, Sopharma AD's revenue was 2.14 billion, an increase of 13.27% compared to the previous year's 1.89 billion. Earnings were 77.85 million, a decrease of -18.89%.